The role of gut hormones in glucose homeostasis.

The gastrointestinal tract has a crucial role in the control of energy homeostasis through its role in the digestion, absorption, and assimilation of ingested nutrients. Furthermore, signals from the gastrointestinal tract are important regulators of gut motility and satiety, both of which have implications for the long-term control of body weight. Among the specialized cell types in the gastrointestinal mucosa, enteroendocrine cells have important roles in regulating energy intake and glucose homeostasis through their actions on peripheral target organs, including the endocrine pancreas. This article reviews the biological actions of gut hormones regulating glucose homeostasis, with an emphasis on mechanisms of action and the emerging therapeutic roles of gut hormones for the treatment of type 2 diabetes mellitus.

[1]  M. Tsai,et al.  Mutant neurogenin-3 in congenital malabsorptive diarrhea. , 2006, The New England journal of medicine.

[2]  David M Nathan,et al.  TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. , 2006, The New England journal of medicine.

[3]  P. Pfluger,et al.  Ghrelin action in the brain controls adipocyte metabolism. , 2006, The Journal of clinical investigation.

[4]  P. Butler,et al.  Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. , 2006, Diabetes care.

[5]  P. Saha,et al.  Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. , 2006, Cell metabolism.

[6]  Josep Vidal,et al.  Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. , 2006, The Journal of clinical endocrinology and metabolism.

[7]  D. Accili,et al.  Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic β-Cell Mass , 2006, Diabetes.

[8]  G. Frost,et al.  Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.

[9]  N. Tajima,et al.  Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats , 2006, Diabetologia.

[10]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[11]  D. Drucker,et al.  Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. , 2006, Diabetes care.

[12]  H. Stefánsson,et al.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.

[13]  Sunmin Park,et al.  Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function* , 2006, Journal of Biological Chemistry.

[14]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[15]  J. Holst,et al.  Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. , 2006, Gastroenterology.

[16]  A. Kaiser.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. , 2005, The New England journal of medicine.

[17]  J. Holst,et al.  Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[19]  J. Holst,et al.  Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia , 2005, Diabetologia.

[20]  W. Suarez-Pinzon,et al.  Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. , 2005, Diabetes.

[21]  J. Holst,et al.  Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients , 2005, Gut.

[22]  Karim Meeran,et al.  Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. , 2005, Diabetes.

[23]  C. Bailey,et al.  Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. , 2005, Diabetes.

[24]  R. Lloyd,et al.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. , 2005, The New England journal of medicine.

[25]  C. Mcintosh,et al.  Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression* , 2005, Journal of Biological Chemistry.

[26]  J. Lakey,et al.  Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. , 2005, The Journal of clinical endocrinology and metabolism.

[27]  A. Young,et al.  Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats , 2005, Diabetologia.

[28]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[29]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[30]  G. Frost,et al.  Ghrelin increases food intake in obese as well as lean subjects , 2004, International Journal of Obesity.

[31]  S. Bloom,et al.  Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth , 1996, Digestive Diseases and Sciences.

[32]  S. Hashiguchi,et al.  Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. , 2004, Diabetes.

[33]  J. Holst,et al.  Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. , 2004, Diabetes.

[34]  M. Pinget,et al.  Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. , 2004, JOP : Journal of the pancreas.

[35]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[36]  A. Astrup,et al.  The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. , 2004, Diabetes care.

[37]  D. Drucker,et al.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.

[38]  J. Ranstam,et al.  Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. , 2004, Diabetes care.

[39]  D. Drucker,et al.  Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. , 2004, Endocrinology.

[40]  Jeppe Sturis,et al.  One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. , 2004, Diabetes.

[41]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[42]  M. Prentki,et al.  Glucagon-like peptide-1 prevents beta cell glucolipotoxicity , 2004, Diabetologia.

[43]  L. Sussel,et al.  Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. McBurney,et al.  Systemic Short-Chain Fatty Acids Rapidly Alter Gastrointestinal Structure, Function, and Expression of Early Response Genes , 1998, Digestive Diseases and Sciences.

[45]  I. Rooman,et al.  Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan , 2004, Diabetologia.

[46]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[47]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[48]  J. Holst,et al.  Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. , 2003, The Journal of clinical investigation.

[49]  P. Jeppesen.  Clinical significance of GLP-2 in short-bowel syndrome. , 2003, The Journal of nutrition.

[50]  P. Brubaker,et al.  Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. , 2003, Canadian journal of physiology and pharmacology.

[51]  Yazhou Li,et al.  Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. , 2003, Gastroenterology.

[52]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[53]  D. Drucker,et al.  Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. , 2003, Diabetes.

[54]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[55]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[56]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[57]  D. Hörsch,et al.  Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. , 2002, The Journal of endocrinology.

[58]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[59]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[60]  T. Hughes,et al.  Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. , 2002, Japanese journal of pharmacology.

[61]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[62]  I. Rooman,et al.  Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. , 2002, Diabetes.

[63]  M. Prentki,et al.  Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation , 2001 .

[64]  D. Smith,et al.  Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.

[65]  D. Hörsch,et al.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.

[66]  R. Pederson,et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.

[67]  J. Holst,et al.  Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. , 2001, Gastroenterology.

[68]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[69]  B. Yusta,et al.  Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. , 2001, Cancer research.

[70]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[71]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[72]  D. Drucker,et al.  Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. , 2000, Endocrinology.

[73]  J. Holst,et al.  Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.

[74]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[76]  D. Drucker,et al.  Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[77]  J. Holst,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes* , 2022 .

[78]  D. Drucker,et al.  The Glucagon Receptor Family , 2000 .

[79]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[80]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[81]  R. Ruff.  Effects of temperature on slow and fast inactivation of rat skeletal muscle Na+channels. , 1999, American journal of physiology. Cell physiology.

[82]  J. Holst,et al.  Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.

[83]  B. Yusta,et al.  Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. , 1999, American journal of physiology. Endocrinology and metabolism.

[84]  A. Edvell,et al.  Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?). , 1999, Endocrinology.

[85]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[86]  J. Holst,et al.  Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans , 1998, Regulatory Peptides.

[87]  M. Wolfe,et al.  Functional GIP receptors are present on adipocytes. , 1998, Endocrinology.

[88]  R. Pederson,et al.  Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.

[89]  P. Hellström,et al.  Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity , 1998, Obesity surgery.

[90]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[91]  D. Drucker,et al.  Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. , 1998, Diabetes.

[92]  J. Holst,et al.  Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling , 1998, Diabetes.

[93]  N. Greig,et al.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. , 1997, The Journal of clinical investigation.

[94]  J. Reeve,et al.  Oxyntomodulin stimulates intestinal glucose uptake in rats. , 1997, Gastroenterology.

[95]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[96]  D. Drucker,et al.  Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard* , 1997, The Journal of Biological Chemistry.

[97]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[98]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[99]  J. Levy,et al.  Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM , 1996, Diabetes.

[100]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[101]  M. McBurney,et al.  Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. , 1996, JPEN. Journal of parenteral and enteral nutrition.

[102]  C. Cheeseman,et al.  The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. , 1996, The American journal of physiology.

[103]  M. McBurney,et al.  Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. , 1996, Endocrinology.

[104]  D. D’Alessio,et al.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. , 1996, The Journal of clinical investigation.

[105]  J. Egan,et al.  Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. , 1995, Endocrinology.

[106]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[107]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[108]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[109]  D. Smith,et al.  Glucagon-like peptide-1 is a physiological incretin in rat. , 1995, The Journal of clinical investigation.

[110]  K. Minaker,et al.  The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects , 1994, Regulatory Peptides.

[111]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[112]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[113]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[114]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[115]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[116]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[117]  D. Beveridge,et al.  Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. , 1992, The Biochemical journal.

[118]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[119]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[120]  J. Habener,et al.  Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. , 1990, The Journal of biological chemistry.

[121]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[122]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[123]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[124]  D. Bataille,et al.  A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. , 1984, Endocrinology.

[125]  R. Modigliani,et al.  Gut hormones in inflammatory bowel disease. , 1983, Scandinavian journal of gastroenterology.

[126]  T. Adrian,et al.  Gut hormone release after intestinal resection. , 1982, Gut.

[127]  John C. Brown.  Gastric Inhibitory Polypeptide , 1982, Monographs on Endocrinology.

[128]  J. Brown,et al.  Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.

[129]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.